Lung Cancer Trials Ask AI to find trials
CompletedPhase 1 / Phase 2NCT00994123
Official study title

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Study summary

A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMM-121 and Erlotinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 22, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?38 U.S. locations

Locations may change over time.

Who runs it?Merrimack Pharmaceuticals

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Merrimack Pharmaceuticals
Interventions being studied
Drug: MM-121; Drug: Erlotinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patients with locally advanced or metastatic non-small cell lung cancer.
  • Patients must be \>/= 18 years of age.
  • Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function.
Reasons someone may not be able to joinExclusion criteria
  • Patients with a recent history (within 5 years) of another malignancy.
  • Patients who are pregnant or nursing.
  • Patients with clinically significant heart failure.
  • Patients with clinically significant eye or gastrointestinal abnormalities.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Study locationBirmingham, Alabama
  • Study locationTucson, Arizona
  • Study locationLoma Linda, California
  • Study locationSacramento, California
  • Study locationSan Francisco, California
  • Study locationAurora, Colorado
  • Study locationTampa, Florida
  • Study locationAtlanta, Georgia
  • Study locationLafayette, Indiana
  • Study locationBoston, Massachusetts
  • Study locationSt Louis, Missouri
  • Study locationBuffalo, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 22, 2016. Always confirm current availability with the study team.

View original record ↗